Synergistic Killing of Staphylococcus aureus by Mefloquine and 18β-Glycyrrhetinic Acid
Microorganisms · 18.11.2026 · 14 (11) · 2677
DOI: 10.3390/microorganisms14112677 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microorganisms, online erschienen am 18.11.2026. Verfasst von Wenwen Cui und 8 weiteren Autor:innen. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Postdoctoral Science Foundation, Jiangsu Provincial Natural Science Foundation Grant, Jiangsu Training Program of Innovation and Entrepreneurship for Undergraduate.
Abstract (Originalsprache)
Infections caused by Staphylococcus aureus, specifically methicillin-resistant S. aureus (MRSA), pose a significant clinical challenge due to their inherent drug resistance. Drug repurposing which involves leveraging clinically approved agents with well-established safety profiles—offers a time- and cost-efficient strategy to bridge this therapeutic gap. This study investigates the synergistic antibacterial effects of the combination of 18β-glycyrrhetinic acid (18β-GA) and mefloquine hydrochloride (Mef) against MRSA, and elucidates the underlying molecular mechanisms of this combination. Our results revealed that the Mef+18β-GA combination effectively promotes anti-MRSA activity by disrupting biofilm integrity and suppressing the expression of key virulence genes, thereby significantly impairing both bacterial proliferation and pathogenicity. Transcriptomic analysis showed that the combination treatment globally modulated gene expression via downregulation of key virulence regulators (agr), adhesion-related genes (clfA, clfB, atl and fib), and antioxidant genes (katE, norB and msrB). We further validated the expression levels of clfA, sigB, katE and agrA by RT-qPCR. In a mouse skin infection model, the Mef+18β-GA combination mitigated skin lesions, reduced inflammatory cytokine levels (IL-1β and IL-6), and efficiently removed MRSA from local lesions and systemic organs. Collectively, these findings indicate that 18β-GA and mefloquine act synergistically against MRSA by targeting bacterial growth, biofilm maturation, antioxidant stress responses, and virulence gene expression. This study provides a promising, translationally relevant drug-repurposing combinatorial strategy for the clinical management of MRSA infections, offering the advantages of proven safety and rapid clinical translatability.
Förderung
- China Postdoctoral Science Foundation
- Jiangsu Provincial Natural Science Foundation Grant
- Jiangsu Training Program of Innovation and Entrepreneurship for Undergraduate
- National Demonstration Center for Experimental Basic Medical Science Education
- National Natural Science Foundation of China
- Science and Technology Program of Hunan Province
Zitieren
APA
Cui, W., Jiang, X., Chen, J., Chen, X., Wan, L., Ren, X., Huang, R., Feng, X., & Yang, H. (2026). Synergistic Killing of Staphylococcus aureus by Mefloquine and 18β-Glycyrrhetinic Acid. Microorganisms, 14(11), 2677. https://doi.org/10.3390/microorganisms14112677
Vancouver
Cui W, Jiang X, Chen J, Chen X, Wan L, Ren X, et al. Synergistic Killing of Staphylococcus aureus by Mefloquine and 18β-Glycyrrhetinic Acid. Microorganisms. 2026;14(11):2677. doi:10.3390/microorganisms14112677
BibTeX
@article{Cui2026,
author = {Cui, Wenwen and Jiang, Xintong and Chen, Junyu and Chen, Xinyu and Wan, Lei and Ren, Xuanyi and Huang, Ruyi and Feng, Xinxin and Yang, Huan},
title = {Synergistic Killing of Staphylococcus aureus by Mefloquine and 18β-Glycyrrhetinic Acid},
journal = {Microorganisms},
year = {2026},
volume = {14},
number = {11},
pages = {2677},
doi = {10.3390/microorganisms14112677}
}
EUVIMED